Di Lauro L, Fattoruso Lorsque, Giacinti L, ainsi que al. Second-range radiation treatment with FOLFIRI in the patients that have metastatic gastric cancer tumors (MGC) not before given fluoropyrimidines. J Clin Oncol. 2009. s (suppl; abstr 4549).
Burtness B, Gibson Yards, Egleston B, ainsi que al. Phase II trial out of docetaxel-irinotecan consolidation inside state-of-the-art esophageal malignant tumors. Ann Oncol. 2009 Jul. 20(7):1242-8. [QxMD MEDLINE Hook up].
A phase II trial evaluating capecitabine and you may irinotecan since the second line therapy during the patients that have oesophago-gastric cancers that progressed toward, or contained in this ninety days off platinum-created chemo
Catenacci DVT, Kang YK, Playground H, mais aussi al. Margetuximab together with pembrolizumab when you look at the clients with previously handled, HER2-confident gastro-oesophageal adenocarcinoma (CP-MGAH22-05): an individual-case, stage 1b-2 demonstration. Lancet Oncol. 2020 Aug. 21 (8):1066-1076. [QxMD MEDLINE Hook]. [Full Text].
Doebele Remote-controlled, Drilon A good, Paz-Ares L, Siena S, ainsi que al. Entrectinib inside customers that have advanced or metastatic NTRK fusion-self-confident solid tumours: incorporated study regarding three-phase step one-dos trials. Lancet Oncol. 2020 Feb. 21 (2):271-282. [QxMD MEDLINE Link]. [Complete Text].
Drilon Good, Laetsch TW, Kummar S, DuBois SG, mais aussi al. Effectiveness out-of Larotrectinib when you look at the TRK Combo-Positive Cancer during the Adults and kids. N Engl J Med. 2018 Feb 22. 378 (8):731-739. [QxMD MEDLINE Hook]. [Full Text message].
Le DT, Durham JN, Smith KN, ainsi que al. Mismatch repair lack forecasts impulse regarding solid tumors so you're able to PD-1 blockade. Research. 2017 Jul twenty eight. 357 (6349):409-413. [QxMD MEDLINE Link].
Ce DT, Uram JN, Wang H, mais aussi al. PD-step one Blockade during the Tumors with Mismatch-Resolve Lack. Letter Engl J Med. 2015 Jun 25. 372 (26):2509-20. [QxMD MEDLINE Hook up].
U. Sahin, O
Tabernero J, Yoshino T, Cohn AL, Obermanucirumab as opposed to placebo in conjunction with next-range FOLFIRI in customers which have metastatic colorectal carcinoma you to definitely progressed during the otherwise once basic-range procedures with bevacizumab, oxaliplatin, and a good fluoropyrimidine (RAISE): an effective randomised, double-blind, multicentre, stage 3 data. Lancet Oncol. 2015 Will get. sixteen (5):499-508. [QxMD MEDLINE Connect]. [Full Text].
Mitani S, Kadowaki S, Komori An effective, Kondoh C, Oze I, Kato K, ainsi que al. A level II Examination of Modified FOLFOX6 having State-of-the-art Gastric Cancers Refractory to Fundamental Therapy. Adv Ther. 2020 Jun. 37 (6):2853-2864. [QxMD MEDLINE Hook]. [Full Text].
Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau An effective, ainsi que al. Trifluridine/tipiracil versus placebo for the people having heavily pretreated metastatic gastric malignant tumors (TAGS): a beneficial randomised, double-blind, placebo-controlled, phase step 3 demonstration. Lancet Oncol. 2018 The fall of. 19 (11):1437-1448. [QxMD MEDLINE Hook].
Kawazoe A beneficial, Ando T, Hosaka H, Fujita J, Koeda K, Nishikawa K, et al. Security and you may pastime from trifluridine/tipiracil and you will ramucirumab from inside the in earlier times treated state-of-the-art gastric cancers: an open-label, single-case, stage dos demo. Lancet Gastroenterol Hepatol. 2021 Mar. 6 (3):209-217. [QxMD MEDLINE Link]. [Full Text message].
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, ainsi que al. A phase 3 study of nivolumab within the in earlier times handled complex gastric otherwise gastroesophageal junction cancer (ATTRACTION-2): 2-year revise study. Gastric Cancer tumors. 2020 Get. 23 (3):510-519. [QxMD MEDLINE Hook]. [Complete Text message].
Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A beneficial, Asayama Yards, mais aussi al. Regorafenib As well as Nivolumab during the Customers That have Cutting-edge Gastric otherwise Colorectal Cancer: An unbarred-Name, Dose-Escalation, and Amount-Expansion Stage Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun 20. 38 (18):2053-2061. [QxMD MEDLINE Hook up]. [Full Text message].
Tureci, Grams. Manikhas, mais aussi. al. FAST: a great randomised phase II examination of zolbetuximab (IMAB362) in addition to EOX instead of EOX alone getting first-line remedy for advanced CLDN18.2-confident gatric and you can gastro-oesophageal adenocarcinoma. Annals from Oncology. 2021 Can get. Vol -619. [Full Text].
Nivolumab extended condition 100 % free emergency in customers that have resected (R0) phase II or III esophageal otherwise gastroesophageal junction cancers exactly who obtained neoadjuvant chemoradiotherapy and had residual pathological disease.
Docetaxel 70-85 milligrams/yards dos IV toward date 1 and additionally cisplatin 70-75 mg/m 2 IV on the big date 1; most of the 21 d [forty-five, 46, 47] or
Javle MM, Yang Grams, Nwogu Le, mais aussi al. Capecitabine, oxaliplatin and radiotherapy: a level IB neoadjuvant analysis to own esophageal cancers that have gene expression study. Disease Dedicate. 2009 Feb. 27(2):193-two hundred. [QxMD MEDLINE Link].
Enzinger Pc, Burtness BA, Niedzwiecki D Norfolk VA backpage escort, Ye X, et al. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Examination of Around three Chemo Regimens Along with Cetuximab from inside the Metastatic Esophageal and you will Gastroesophageal Aug 10. 34 (23):2736-42. [QxMD MEDLINE Hook up]. [Full Text message].
Albertsson Yards, Johansson B, Friesland S, et al. Stage II training to the docetaxel by yourself all of the 3rd week, or weekly in conjunction with gemcitabine in the people which have number 1 in your area complex, metastatic, otherwise recurrent esophageal disease. Med Oncol. 2007. 24(4):407-a dozen. [QxMD MEDLINE Connect].
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy having in the past addressed cutting-edge gastric or gastro-oesophageal junction adenocarcinoma (REGARD): a worldwide, randomised, multicentre, placebo-managed, phase step three trial. Lancet. 2014 The month of january 4. 383(9911):31-nine. [QxMD MEDLINE Hook up].